Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HTBX - Heat Biologics Inc


Close
2.38
0.010   0.420%

Share volume: 43,610
Last Updated: Mon 02 May 2022 10:00:00 PM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$2.37
0.01
0.42%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
29%
Profitability 27%
Dept financing 10%
Liquidity 33%
Performance 35%
Company vs Stock growth
vs
Performance
5 Days
-2.46%
1 Month
-22.98%
3 Months
-14.39%
6 Months
-56.33%
1 Year
-65.36%
2 Year
-38.22%
Key data
Stock price
$2.38
P/E Ratio 
0.00
DAY RANGE
$2.33 - $2.48
EPS 
$0.00
52 WEEK RANGE
$2.07 - $10.85
52 WEEK CHANGE
-$0.67
MARKET CAP 
61.047 M
YIELD 
N/A
SHARES OUTSTANDING 
25.650 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$71,734
AVERAGE 30 VOLUME 
$165,822
Company detail
CEO: Jeffrey Wolf
Region: US
Website: www.heatbio.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

Recent news